Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice

Hepatology

Volumn 63, Issue 4, 2016, Pages 1190-1204

  Gariani, Karim ^a   Menzies, Keir J ^a,b   Ryu, Dongryeol ^a   Wegner, Casey J ^c   Wang, Xu ^a   Ropelle, Eduardo R ^d   Moullan, Norman ^a   Zhang, Hongbo ^a   Perino, Alessia ^a   Lemos, Vera ^a   Kim, Bohkyung ^c   Park, Young Ki ^c   Piersigilli, Alessandra ^a,e   Pham, Tho X ^c   Yang, Yue ^c   Ku, Chai Siah ^c   Koo, Sung I ^c   Fomitchova, Anna ^c   Cantó, Carlos ^f   Schoonjans, Kristina ^a   Sauve, Anthony A ^g   Lee, Ji Young ^c   Auwerx, Johan ^a   more..

^a EPFL   (Switzerland)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e UNIVERSITY OF BERN   (Switzerland)

^f NESTLÉ RESEARCH CENTER   (Switzerland)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN E; CHOLESTEROL; EARLY PREGNANCY FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE RIBOSIDE; SIRTUIN 1; SIRTUIN 3; SUCROSE; TRIACYLGLYCEROL; NICOTINAMIDE; NICOTINAMIDE-BETA-RIBOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; CELL FUNCTION; CHOLESTEROL DIET; DIET SUPPLEMENTATION; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; HOMEOSTASIS; IN VIVO STUDY; LIMIT OF QUANTITATION; LIPID DIET; LIPID METABOLISM; LIVER FUNCTION; MALE; MITOCHONDRIAL BIOGENESIS; MITOCHONDRIAL DNA DISORDER; MITOCHONDRION; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UNFOLDED PROTEIN RESPONSE; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; FATTY LIVER; IMMUNOHISTOCHEMISTRY; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOPSY, NEEDLE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FATTY LIVER; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MALE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; NAD; NIACINAMIDE; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNFOLDED PROTEIN RESPONSE;

EID: 84950327004     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28245     Document Type: Article

References (43)

1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519-1523.
2. Shaker M, Tabbaa A, Albeldawi M, Alkhouri N. Liver transplantation for nonalcoholic fatty liver disease: new challenges and new opportunities. World J Gastroenterol 2014;20:5320-5330.
3. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
4. Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol 2014;5:277-286.
5. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
6. Begriche K, Massart J, Robin MA, Bonnet F, Fromenty B. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease. Hepatology 2013;58:1497-1507.
7. Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 2002;37:56-62.
8. Gentric G, Maillet V, Paradis V, Couton D, L'Hermitte A, Panasyuk G, et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease. J Clin Invest 2015;125:981-992.
9. Pirinen E, Canto C, Jo YS, Morato L, Zhang H, Menzies KJ, et al. Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 2014;19:1034-1041.
10. Canto C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15:838-847.
11. Yoshino J, Mills KF, Yoon MJ, Imai SI. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab 2011;14:528-536.
12. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsstrom S, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 2014;6:721-731.
13. van de Weijer T, Phielix E, Bilet L, Williams EG, Ropelle ER, Bierwagen A, et al. Evidence for a direct effect of the NAD+ precursor Acipimox on muscle mitochondrial function in humans. Diabetes 2015;64:1193-1201.
14. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, et al. NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab 2014;19:1042-1049.
15. Houtkooper RH, Canto C, Wanders RJ, Auwerx J. The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev 2010;31:194-223.
16. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab 2012;15:838-847.
17. Nikiforov A, Dolle C, Niere M, Ziegler M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem 2011;286:21767-21778.
18. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 2004;117:495-502.
19. Tous M, Ferré N, Camps J, Riu F, Joven J. Feeding apolipoprotein E-knockout mice with cholesterol and fat enriched diets may be a model of non-alcoholic steatohepatitis. Mol Cell Biochem 2005;268:53-58.
20. Verbeek J, Lannoo M, Pirinen E, Ryu D, Spincemaille P, Vander Elst I, et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut 2015;64:673-683.
21. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, et al. The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 2013;154:430-441.
22. Jo YS, Ryu D, Maida A, Wang X, Evans RM, Schoonjans K, Auwerx J. Phosphorylation of the nuclear receptor co-repressor 1 by protein kinase B (PKB/Akt) switches its co-repressor targets in the liver. Hepatology 2015 May 22. doi: 10.1002/hep.27907. [Epub ahead of print]
23. Fernandez-Marcos PJ, Jeninga EH, Cantó C, Harach T, de Boer VC, Andreux P, et al. Muscle or liver-specific Sirt3 deficiency induces hyperacetylation of mitochondrial proteins without affecting global metabolic homeostasis. Sci Rep 2012;2:425.
24. Stein S, Oosterveer MH, Mataki C, Xu P, Lemos V, Havinga R, et al. SUMOylation-dependent LRH-1/PROX1 interaction promotes atherosclerosis by decreasing hepatic reverse cholesterol transport. Cell Metab 2014;20:603-613.
25. Yang T, Sauve AA. NAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicity. AAPS J 2006;8:E632-E643.
26. Wu Y, Williams EG, Dubuis S, Mottis A, Jovaisaite V, Houten SM, et al. Multilayered genetic and omics dissection of mitochondrial activity in a mouse reference population. Cell 2014;158:1415-1430.
27. Tummala KS, Gomes AL, Yilmaz M, Graña O, Bakiri L, Ruppen I, et al. Inhibition of De Novo NAD(+) Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage. Cancer Cell 2014;26:826-839.
28. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, et al. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 2008;6:e107.
29. Mukhopadhyay P, Rajesh M, Cao Z, Horvath B, Park O, Wang H, et al. Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 2013;59:1998-2009.
30. Hasenfuss SC, Bakiri L, Thomsen MK, Williams EG, Auwerx J, Wagner EF. Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab 2014;19:84-95.
31. Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology. Biochim Biophys Acta 2007;1771:999-1013.
32. Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, et al. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004;40:972-980.
33. Akiyama TE, Nicol CJ, Fievet C, Staels B, Ward JM, Auwerx J, et al. Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 2001;276:39088-39093.
34. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008;134:405-415.
35. Houtkooper RH, Mouchiroud L, Ryu D, Moullan N, Katsyuba E, Knott G, et al. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature 2013;497:451-457.
36. Gomes AP, Price NL, Ling AJ, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 2013;155:1624-1638.
37. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2011;54:795-809.
38. Papa L, Germain D. SirT3 regulates the mitochondrial unfolded protein response. Mol Cell Biol 2014;34:699-710.
39. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab 2015;22:31-53.
40. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsström S, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med 2014;6:721-731.
41. Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 2014;508:258-262.
42. Marmier S, Dentin R, Daujat-Chavanieu M, Guillou H, Bertrand-Michel J, Gerbal-Chaloin S, et al. Novel role for carbohydrate responsive element binding protein in the control of ethanol metabolism and susceptibility to binge drinking. Hepatology 2015;62:1086-1100.
43. Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 2011;178:946-955.